Symbols / ENGN $7.24 +8.22% enGene Holdings Inc.
ENGN Chart
About
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 485.00M |
| Enterprise Value | 205.68M | Income | -122.44M | Sales | — |
| Book/sh | 4.20 | Cash/sh | 4.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 81 | IPO | — |
| P/E | — | Forward P/E | -3.81 | PEG | — |
| P/S | — | P/B | 1.72 | P/C | — |
| EV/EBITDA | -1.62 | EV/Sales | — | Quick Ratio | 11.36 |
| Current Ratio | 11.75 | Debt/Eq | 11.89 | LT Debt/Eq | — |
| EPS (ttm) | -2.25 | EPS next Y | -1.90 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-09 07:00 | ROA | -25.63% |
| ROE | -46.07% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 66.99M |
| Shs Float | 26.44M | Short Float | 1.77% | Short Ratio | 1.76 |
| Short Interest | — | 52W High | 12.25 | 52W Low | 2.65 |
| Beta | -0.05 | Avg Volume | 430.75K | Volume | 218.19K |
| Target Price | $23.27 | Recom | Strong_buy | Prev Close | $6.69 |
| Price | $7.24 | Change | 8.22% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Oppenheimer | Outperform → Outperform | $30 |
| 2026-03-09 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-11-12 | main | Morgan Stanley | Overweight → Overweight | $19 |
| 2025-11-12 | reit | Oppenheimer | Outperform → Outperform | $33 |
| 2025-11-12 | main | UBS | Neutral → Neutral | $10 |
| 2025-11-12 | main | Citizens | Market Outperform → Market Outperform | $21 |
| 2025-09-12 | main | Morgan Stanley | Overweight → Overweight | $18 |
| 2025-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-04-29 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2025-03-11 | main | Morgan Stanley | Overweight → Overweight | $34 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-18 | init | Piper Sandler | — → Overweight | $26 |
| 2025-02-14 | down | UBS | Buy → Neutral | $7 |
| 2024-12-23 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-12-23 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2024-12-06 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-11-27 | init | Raymond James | — → Outperform | $23 |
| 2024-11-18 | init | JMP Securities | — → Market Outperform | $18 |
| 2024-09-24 | reit | Oppenheimer | Outperform → Outperform | $30 |
- Experimental bladder cancer treatment from enGene aims for FDA review in 2026 - Stock Titan Mon, 09 Mar 2026 07
- Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail Fri, 03 Apr 2026 11
- enGene Holdings: Key Catalysts Incoming For 2026 (NASDAQ:ENGN) - Seeking Alpha hu, 12 Mar 2026 07
- ENGN Stock Price and Chart — NASDAQ:ENGN - TradingView ue, 23 Sep 2025 07
- ENGN Stock Soars On Hopeful Data From Bladder Cancer Study - Stocktwits ue, 11 Nov 2025 08
- enGene stock rises after detalimogene shows improved response rate in bladder cancer - Investing.com ue, 11 Nov 2025 08
- enGene (NASDAQ:ENGN) Shares Gap Down - Here's Why - MarketBeat Mon, 09 Mar 2026 07
- enGene Holdings Inc (ENGN) Income Statement - TradingKey hu, 02 Apr 2026 20
- Genetic medicines firm enGene to speak at four major healthcare investor events - Stock Titan Fri, 20 Feb 2026 08
- enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 25.3% in March - MarketBeat Sun, 29 Mar 2026 17
- Raymond James reiterates Engene Holdings stock Strong Buy rating - Investing.com Mon, 09 Mar 2026 07
- enGene extends momentum with another 14% surge on Friday (ENGN:NASDAQ) - Seeking Alpha Fri, 23 Jan 2026 08
- Biotech enGene secures $125M to advance bladder cancer treatment detalimogene - Stock Titan ue, 20 Jan 2026 08
- enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat hu, 26 Mar 2026 07
- enGene (Nasdaq: ENGN) reports 62% CR at 6 months in NMIBC; LEGEND enrollment completed - Stock Titan ue, 11 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
123.17
+97.71%
|
62.30
+139.05%
|
26.06
+34.14%
|
19.43
|
| Research And Development |
|
94.48
+146.59%
|
38.31
+132.80%
|
16.46
+6.41%
|
15.47
|
| Selling General And Administration |
|
28.68
+19.61%
|
23.98
+183.14%
|
8.47
+159.82%
|
3.26
|
| General And Administrative Expense |
|
28.68
+19.61%
|
23.98
+183.14%
|
8.47
+159.82%
|
3.26
|
| Salaries And Wages |
|
17.21
+43.08%
|
12.03
+151.69%
|
4.78
+132.60%
|
2.06
|
| Other Gand A |
|
11.47
-4.02%
|
11.95
+223.88%
|
3.69
+206.22%
|
1.21
|
| Other Operating Expenses |
|
—
|
1.88
+65.99%
|
1.13
+61.71%
|
0.70
|
| Total Expenses |
|
123.17
+97.71%
|
62.30
+139.05%
|
26.06
+34.14%
|
19.43
|
| Operating Income |
|
-123.17
-97.71%
|
-62.30
-139.05%
|
-26.06
-34.14%
|
-19.43
|
| Total Operating Income As Reported |
|
-123.17
-97.71%
|
-62.30
-139.05%
|
-26.06
-34.14%
|
-19.43
|
| EBITDA |
|
-113.80
-118.68%
|
-52.04
+45.09%
|
-94.77
-316.05%
|
-22.78
|
| Normalized EBITDA |
|
-113.80
-120.22%
|
-51.67
+36.29%
|
-81.11
-311.26%
|
-19.72
|
| Reconciled Depreciation |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| EBIT |
|
-114.31
-118.30%
|
-52.36
+44.85%
|
-94.95
-312.51%
|
-23.02
|
| Total Unusual Items |
|
0.00
+100.00%
|
-0.37
+97.32%
|
-13.66
-346.94%
|
-3.06
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-0.37
+97.32%
|
-13.66
-346.94%
|
-3.06
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.37
+88.16%
|
-3.09
|
0.00
|
| Other Special Charges |
|
—
|
0.37
-88.16%
|
3.09
|
—
|
| Net Income |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Pretax Income |
|
-117.30
-112.65%
|
-55.16
+44.78%
|
-99.90
-308.76%
|
-24.44
|
| Net Non Operating Interest Income Expense |
|
6.43
-15.54%
|
7.62
+298.51%
|
-3.84
-196.45%
|
-1.29
|
| Interest Expense Non Operating |
|
2.99
+7.01%
|
2.80
-43.51%
|
4.95
+248.07%
|
1.42
|
| Net Interest Income |
|
6.43
-15.54%
|
7.62
+298.51%
|
-3.84
-196.45%
|
-1.29
|
| Interest Expense |
|
2.99
+7.01%
|
2.80
-43.51%
|
4.95
+248.07%
|
1.42
|
| Interest Income Non Operating |
|
9.43
-9.48%
|
10.41
+832.23%
|
1.12
+765.89%
|
0.13
|
| Interest Income |
|
9.43
-9.48%
|
10.41
+832.23%
|
1.12
+765.89%
|
0.13
|
| Other Income Expense |
|
-0.57
-18.79%
|
-0.48
+99.32%
|
-70.00
-1782.33%
|
-3.72
|
| Other Non Operating Income Expenses |
|
-0.57
-403.54%
|
-0.11
+99.80%
|
-56.34
-8410.73%
|
-0.66
|
| Gain On Sale Of Security |
|
—
|
—
|
-10.57
-245.83%
|
-3.06
|
| Tax Provision |
|
0.00
+100.00%
|
-0.02
-211.76%
|
0.02
-22.73%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
-99.93%
|
0.00
+52.61%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.00
+100.00%
|
-5.47
-582.09%
|
-0.80
|
| Net Income Including Noncontrolling Interests |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Net Income From Continuing Operation Net Minority Interest |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Net Income From Continuing And Discontinued Operation |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Net Income Continuous Operations |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Normalized Income |
|
-117.30
-114.15%
|
-54.78
+40.28%
|
-91.72
-313.03%
|
-22.21
|
| Net Income Common Stockholders |
|
-117.30
-112.73%
|
-55.14
+47.35%
|
-104.74
-260.87%
|
-29.02
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
0.00
|
| Diluted EPS |
|
-2.29
-56.85%
|
-1.46
+67.66%
|
-4.52
-260.87%
|
-1.25
|
| Basic EPS |
|
-2.29
-56.85%
|
-1.46
+67.66%
|
-4.52
-260.87%
|
-1.25
|
| Basic Average Shares |
|
51.12
+35.30%
|
37.78
+62.87%
|
23.20
+0.00%
|
23.20
|
| Diluted Average Shares |
|
51.12
+35.30%
|
37.78
+62.87%
|
23.20
+0.00%
|
23.20
|
| Diluted NI Availto Com Stockholders |
|
-117.30
-112.73%
|
-55.14
+47.35%
|
-104.74
-260.87%
|
-29.02
|
| Preferred Stock Dividends |
|
—
|
—
|
4.82
+5.70%
|
4.56
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Assets |
|
221.47
-28.83%
|
311.17
+257.84%
|
86.96
+263.71%
|
23.91
|
| Current Assets |
|
201.39
-18.58%
|
247.36
+189.52%
|
85.44
+278.34%
|
22.58
|
| Cash Cash Equivalents And Short Term Investments |
|
193.74
-18.71%
|
238.33
+192.36%
|
81.52
+298.95%
|
20.43
|
| Cash And Cash Equivalents |
|
50.15
-71.01%
|
173.00
+112.22%
|
81.52
+298.95%
|
20.43
|
| Other Short Term Investments |
|
143.58
+119.79%
|
65.33
|
0.00
|
—
|
| Receivables |
|
0.93
+179.22%
|
0.33
-85.83%
|
2.34
+75.37%
|
1.34
|
| Taxes Receivable |
|
0.93
+179.22%
|
0.33
-85.83%
|
2.34
+75.37%
|
1.34
|
| Restricted Cash |
|
0.08
+9.72%
|
0.07
-5.26%
|
0.08
+2.70%
|
0.07
|
| Other Current Assets |
|
6.65
-22.92%
|
8.63
+475.07%
|
1.50
+102.98%
|
0.74
|
| Total Non Current Assets |
|
20.08
-68.54%
|
63.81
+4100.86%
|
1.52
+14.56%
|
1.33
|
| Net PPE |
|
10.19
+250.27%
|
2.91
+394.06%
|
0.59
+52.20%
|
0.39
|
| Gross PPE |
|
12.30
+172.04%
|
4.52
+95.16%
|
2.32
+19.38%
|
1.94
|
| Accumulated Depreciation |
|
-2.10
-30.62%
|
-1.61
+6.77%
|
-1.73
-11.20%
|
-1.55
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
7.72
+343.19%
|
1.74
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.18
+239.26%
|
0.35
-14.46%
|
0.41
+17.92%
|
0.35
|
| Other Properties |
|
3.13
+43.04%
|
2.19
+23.16%
|
1.78
+20.86%
|
1.47
|
| Leases |
|
0.26
+9.62%
|
0.24
+85.27%
|
0.13
+5.74%
|
0.12
|
| Investments And Advances |
|
8.52
-85.68%
|
59.53
|
0.00
|
—
|
| Other Non Current Assets |
|
1.36
-0.87%
|
1.37
+47.74%
|
0.93
-0.96%
|
0.94
|
| Total Liabilities Net Minority Interest |
|
53.76
+39.41%
|
38.56
+166.43%
|
14.47
-69.47%
|
47.41
|
| Current Liabilities |
|
31.98
+118.12%
|
14.66
+178.89%
|
5.26
+3.00%
|
5.10
|
| Payables And Accrued Expenses |
|
17.33
+76.17%
|
9.84
+161.12%
|
3.77
+19.13%
|
3.16
|
| Payables |
|
6.71
+375.34%
|
1.41
+18.08%
|
1.20
+60.40%
|
0.74
|
| Accounts Payable |
|
6.69
+373.99%
|
1.41
+22.06%
|
1.16
+59.89%
|
0.72
|
| Current Accrued Expenses |
|
10.63
+26.08%
|
8.43
+227.56%
|
2.57
+6.41%
|
2.42
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.05
+16.63%
|
3.48
+326.90%
|
0.81
+20.41%
|
0.68
|
| Total Tax Payable |
|
0.02
|
0.00
-100.00%
|
0.04
+77.27%
|
0.02
|
| Income Tax Payable |
|
0.02
|
0.00
-100.00%
|
0.04
+77.27%
|
0.02
|
| Current Debt And Capital Lease Obligation |
|
10.02
+792.69%
|
1.12
+99.64%
|
0.56
-55.57%
|
1.26
|
| Current Debt |
|
8.00
+1044.78%
|
0.70
+24.38%
|
0.56
-55.57%
|
1.26
|
| Other Current Borrowings |
|
8.00
+1044.78%
|
0.70
+24.38%
|
0.56
-55.57%
|
1.26
|
| Current Capital Lease Obligation |
|
2.01
+376.12%
|
0.42
|
0.00
|
0.00
|
| Other Current Liabilities |
|
0.58
+156.44%
|
0.23
+99.12%
|
0.11
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
21.78
-8.87%
|
23.90
+159.33%
|
9.22
-78.21%
|
42.30
|
| Long Term Debt And Capital Lease Obligation |
|
21.78
-8.87%
|
23.90
+159.33%
|
9.22
-70.12%
|
30.84
|
| Long Term Debt |
|
15.32
-31.81%
|
22.47
+143.85%
|
9.22
-70.12%
|
30.84
|
| Long Term Capital Lease Obligation |
|
6.46
+352.35%
|
1.43
|
0.00
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
0.00
-100.00%
|
53.12
|
| Stockholders Equity |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+408.50%
|
-23.50
|
| Common Stock Equity |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+194.61%
|
-76.61
|
| Capital Stock |
|
513.28
+0.68%
|
509.81
+96.56%
|
259.37
+273.16%
|
69.51
|
| Common Stock |
|
513.28
+0.68%
|
509.81
+96.56%
|
259.37
+1482.51%
|
16.39
|
| Preferred Stock |
|
—
|
—
|
0.00
-100.00%
|
53.12
|
| Share Issued |
|
52.02
+2.04%
|
50.98
+119.75%
|
23.20
+0.00%
|
23.20
|
| Ordinary Shares Number |
|
52.02
+2.04%
|
50.98
+119.75%
|
23.20
+0.00%
|
23.20
|
| Additional Paid In Capital |
|
27.35
+44.32%
|
18.95
+38.15%
|
13.72
+78.54%
|
7.68
|
| Retained Earnings |
|
-372.03
-46.05%
|
-254.73
-27.63%
|
-199.59
-100.25%
|
-99.67
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.89
+37.42%
|
-1.42
-39.67%
|
-1.02
+0.00%
|
-1.02
|
| Other Equity Adjustments |
|
-0.89
+37.42%
|
-1.42
-39.67%
|
-1.02
+0.00%
|
-1.02
|
| Total Equity Gross Minority Interest |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+408.50%
|
-23.50
|
| Total Capitalization |
|
183.03
-37.97%
|
295.08
+261.17%
|
81.70
+1011.74%
|
7.35
|
| Working Capital |
|
169.41
-27.20%
|
232.70
+190.21%
|
80.18
+358.74%
|
17.48
|
| Invested Capital |
|
191.04
-35.41%
|
295.78
+259.55%
|
82.26
+284.85%
|
-44.50
|
| Total Debt |
|
31.80
+27.07%
|
25.02
+155.90%
|
9.78
-69.55%
|
32.11
|
| Net Debt |
|
—
|
—
|
—
|
11.68
|
| Capital Lease Obligations |
|
8.47
+357.78%
|
1.85
|
0.00
|
0.00
|
| Net Tangible Assets |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+408.50%
|
-23.50
|
| Tangible Book Value |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+194.61%
|
-76.61
|
| Available For Sale Securities |
|
8.52
-85.68%
|
59.53
|
—
|
—
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
11.46
|
| Investmentin Financial Assets |
|
8.52
-85.68%
|
59.53
|
0.00
|
—
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
53.12
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-99.24
-105.54%
|
-48.28
-95.13%
|
-24.74
-40.65%
|
-17.59
|
| Cash Flow From Continuing Operating Activities |
|
-99.24
-105.54%
|
-48.28
-95.13%
|
-24.74
-40.65%
|
-17.59
|
| Net Income From Continuing Operations |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Depreciation Amortization Depletion |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| Depreciation |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| Depreciation And Amortization |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| Other Non Cash Items |
|
1.23
+27.14%
|
0.97
-43.07%
|
1.70
+166.35%
|
0.64
|
| Stock Based Compensation |
|
9.65
+81.18%
|
5.32
+54.32%
|
3.45
+2874.14%
|
0.12
|
| Operating Gains Losses |
|
0.00
-99.21%
|
0.38
-97.30%
|
14.15
+282.18%
|
3.70
|
| Gain Loss On Investment Securities |
|
—
|
—
|
10.57
+245.83%
|
3.06
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.00
-100.00%
|
56.21
|
0.00
|
| Net Foreign Currency Exchange Gain Loss |
|
0.00
+150.00%
|
-0.01
-101.23%
|
0.49
-24.30%
|
0.65
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.02
|
0.00
|
—
|
| Change In Working Capital |
|
9.74
+10152.63%
|
0.10
+118.38%
|
-0.52
-123.78%
|
2.17
|
| Change In Receivables |
|
-0.59
-129.59%
|
2.01
+299.70%
|
-1.01
-804.20%
|
0.14
|
| Change In Prepaid Assets |
|
1.99
+126.29%
|
-7.57
-907.46%
|
-0.75
-564.60%
|
-0.11
|
| Change In Payables And Accrued Expense |
|
8.07
+41.64%
|
5.70
+359.23%
|
1.24
-42.12%
|
2.14
|
| Change In Accrued Expense |
|
3.13
-40.10%
|
5.22
+501.96%
|
0.87
-62.92%
|
2.34
|
| Change In Payable |
|
4.94
+942.62%
|
0.47
+27.08%
|
0.37
+289.34%
|
-0.20
|
| Change In Account Payable |
|
4.94
+942.62%
|
0.47
+27.08%
|
0.37
+289.34%
|
-0.20
|
| Change In Other Current Liabilities |
|
0.27
+659.18%
|
-0.05
|
0.00
|
—
|
| Investing Cash Flow |
|
-25.14
+80.04%
|
-125.95
-39507.86%
|
-0.32
-107.84%
|
-0.15
|
| Cash Flow From Continuing Investing Activities |
|
-25.14
+80.04%
|
-125.95
-39507.86%
|
-0.32
-107.84%
|
-0.15
|
| Net PPE Purchase And Sale |
|
-1.49
-60.54%
|
-0.93
-190.88%
|
-0.32
-107.84%
|
-0.15
|
| Purchase Of PPE |
|
-1.49
-60.54%
|
-0.93
-190.88%
|
-0.32
-107.84%
|
-0.15
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-1.49
-60.54%
|
-0.93
-190.88%
|
-0.32
-107.84%
|
-0.15
|
| Net Investment Purchase And Sale |
|
-23.65
+81.08%
|
-125.03
|
0.00
|
—
|
| Purchase Of Investment |
|
-160.84
-28.65%
|
-125.03
|
0.00
|
—
|
| Sale Of Investment |
|
137.19
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
1.52
-99.43%
|
265.72
+208.44%
|
86.15
+208.03%
|
27.97
|
| Cash Flow From Continuing Financing Activities |
|
1.52
-99.43%
|
265.72
+208.44%
|
86.15
+208.03%
|
27.97
|
| Net Issuance Payments Of Debt |
|
-0.70
-105.35%
|
13.05
-60.76%
|
33.27
+17.19%
|
28.39
|
| Issuance Of Debt |
|
0.00
-100.00%
|
22.50
-40.79%
|
38.00
+29.25%
|
29.40
|
| Repayment Of Debt |
|
-0.70
+92.60%
|
-9.45
-99.64%
|
-4.73
-368.42%
|
-1.01
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
22.50
-40.79%
|
38.00
+29.25%
|
29.40
|
| Long Term Debt Payments |
|
-0.70
+92.60%
|
-9.45
-99.64%
|
-4.73
-368.42%
|
-1.01
|
| Net Long Term Debt Issuance |
|
-0.70
-105.35%
|
13.05
-60.76%
|
33.27
+17.19%
|
28.39
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
260.15
+357.27%
|
56.89
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.22
-63.53%
|
6.10
+13754.55%
|
0.04
+266.67%
|
0.01
|
| Net Other Financing Charges |
|
—
|
-13.58
-234.75%
|
-4.06
-832.87%
|
-0.43
|
| Changes In Cash |
|
-122.85
-234.29%
|
91.48
+49.76%
|
61.09
+497.59%
|
10.22
|
| Effect Of Exchange Rate Changes |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+100.12%
|
-0.81
|
| Beginning Cash Position |
|
173.00
+112.22%
|
81.52
+298.95%
|
20.43
+85.48%
|
11.02
|
| End Cash Position |
|
50.15
-71.01%
|
173.00
+112.22%
|
81.52
+298.95%
|
20.43
|
| Free Cash Flow |
|
-100.72
-104.70%
|
-49.21
-96.34%
|
-25.06
-41.23%
|
-17.75
|
| Interest Paid Supplemental Data |
|
2.29
+18.91%
|
1.93
+37.70%
|
1.40
+127.32%
|
0.61
|
| Amortization Of Securities |
|
-3.07
-1221.98%
|
-0.23
|
0.00
|
—
|
| Common Stock Issuance |
|
0.00
-100.00%
|
260.15
+357.27%
|
56.89
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
260.15
+357.27%
|
56.89
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-09 View
- 10-Q2026-03-09 View
- 8-K2026-03-09 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 8-K2026-01-21 View
- 8-K2026-01-21 View
- 10-K2025-12-22 View
- 8-K2025-12-22 View
- 8-K2025-11-14 View
- 8-K2025-11-12 View
- 8-K2025-10-02 View
- 42025-10-01 View
- 8-K2025-09-30 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|